President Donald Trump has taken a significant step in the ongoing debate over the therapeutic potential of psychedelic substances, signing an executive order that directs the FDA to expedite the review of these drugs. The move is aimed at speeding up access to medical research and treatment based on substances like ibogaine, a non-narcotic alkaloid that has been touted by some as a potentially game-changing treatment for post-traumatic stress disorder (PTSD) among US military veterans. Proponents of ibogaine and other psychedelic substances argue that they can offer new avenues of treatment for a range of mental health conditions, and that the current regulatory framework is hindering progress in this area. With this executive order, Trump is effectively giving the green light for the FDA to move more quickly in evaluating the safety and efficacy of these substances, potentially paving the way for new treatments and therapies.
President signed executive order directing FDA to expedite review of psychedelic drugs including ibogaineDonald Trump on Saturday announced reforms intended to speed up access to medical research and treatment based on psychedelic drugs.The president signed an executive order directing the federal Food and Drug Administration (FDA) to expedite review of drugs such as ibogaine, a drug that US military veteran groups have said can help treat post-traumatic stress disorder. Continue reading...
